{"id":"NCT03049735","sponsor":"Myovant Sciences GmbH","briefTitle":"LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","officialTitle":"LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-26","primaryCompletion":"2019-04-29","completion":"2020-08-24","firstPosted":"2017-02-10","resultsPosted":"2022-04-19","lastUpdate":"2022-04-19"},"enrollment":388,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Heavy Menstrual Bleeding","Uterine Fibroid"],"interventions":[{"type":"DRUG","name":"Relugolix","otherNames":["TAK-385","MVT-601"]},{"type":"DRUG","name":"Estradiol/norethindrone acetate","otherNames":["E2/NETA","low-dose hormonal add-back"]},{"type":"DRUG","name":"Estradiol/norethindrone acetate placebo","otherNames":[]},{"type":"DRUG","name":"Relugolix placebo","otherNames":[]}],"arms":[{"label":"Relugolix plus E2/NETA (Group A)","type":"EXPERIMENTAL"},{"label":"Relugolix plus Delayed E2/NETA (Group B)","type":"EXPERIMENTAL"},{"label":"Placebo (Group C)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.","primaryOutcome":{"measure":"Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A â‰¥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA","timeFrame":"From Baseline up to last 35 days of treatment (up to Week 24)","effectByArm":[{"arm":"Relugolix Plus E2/NETA (Group A)","deltaMin":73.4,"sd":null},{"arm":"Placebo (Group C)","deltaMin":18.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":110,"countries":["United States","Brazil","Italy","Poland","South Africa","United Kingdom"]},"refs":{"pmids":["39466126","37863160","37477173","37183454","36357960","35675604","35415708","33596357"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":128},"commonTop":["Hot flush","Headache","Arthralgia","Upper respiratory tract infection","Hypertension"]}}